Pixee Fox, who has undergone many plastic surgeries from eye color implant to breast implant, butt lifting, and 6 ribs removal, travelled to Istanbul last week to be one step closer to her dream of becoming a cartoon character. Pixee shared the results of her Spider Web non surgical Face Lifting procedure, which was developed by Aesthetic Surgeon Bülent Cihantimur M.D.
Dr. Bülent Cihantimur, who listened to and examined Pixee Fox at his Istabul Byomed clinic prior to application, said: “Pixee was in need of a solution for her round face. She said she did not like her U shaped face and was looking for a V shaped contour line. Upon a friend’s recommendation, she went on my website and researched about Spider Web Face Lifting. After making contact, she came to Istanbul to undergo the Spider Web Face Lifting.”
Cihantimur contıunes: “The Spider Web Technique is a non-surgical procedure that shrinks, rejuvenates, and forms the face. In this technique I developed, fine needles are used to net medical threads that can dissolve just like a spider’s web under the skin. The body reacts to these threads and nets its own biological net around them. It boosts collagen production and increases lowered elastin.”
PicoWay incorporates the highest peak power and the shortest pulse durations of any aesthetic laser in the market. The combination of these two technological breakthroughs creates the strongest photo-mechanical impact, which enables the most safe and effective fracturing of tattoo ink or pigmentation. The revolutionary PicoWay technology is integrated into a proven, reliable Candela™ platform which ensures superior performance and low cost of ownership.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762556-syneron-launch-picoway-picosecond/
Smith & Nephew plc (LSE: SN, NYSE: SNN), the global medical technology business, announces the FDA clearance of the pocket-sized PICO◊ system, a single use Negative Pressure Wound Therapy (NPWT) system. PICO is cleared for use both in a hospital and homecare setting and expands the use of NPWT from the traditional wound care population to include a wider range of patients undergoing orthopaedic surgery, plastic surgery and general surgical procedures. This FDA clearance follows the recent successful launch of PICO in Europe, Canada, and Australia.
To view Multimedia News Release, go to http://www.multivu.com/mnr/51011-smith-nephew-pico-system-fda-approval-npwt
The legend of thai massage and medicine began more than two centuries ago at Wat Po-a temple which also became Thailand\\\\\\\'s first ever university. Wat Po is a bastion of Thai medical heritage and thai massage, and with astonishing foresight the founded the Wat Po Traditonal Medical School more than 60 years ago.
Royal Philips Electronics (NYSE: PHG, AEX: PHI) today introduced the HomeLox portable liquid oxygen system. The innovative system enables oxygen users to generate and store the liquid form of oxygen in the home setting. The HomeLox system offers users the long-lasting and lightweight characteristics of traditional liquid systems, while freeing them from difficulties of filling and dependence on deliveries associated with conventional systems.
Home oxygen is a critical, life-sustaining medical treatment prescribed to nearly 1.5 million Medicare patients annually who suffer from respiratory illnesses such as chronic obstructive pulmonary disease (COPD).
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/philips/45648/
To speed progress against cancer and other diseases, the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project today announced the largest-ever release of comprehensive human cancer genome data for free access by the global scientific community. The amount of information released more than doubles the volume of high-coverage, whole genome data currently available from all human genome sources combined. This information is valuable not just to cancer researchers, but also to scientists studying almost any disease.
To view Multimedia News Release, go to http://www.multivu.com/mnr/52993-st-jude-childrens-research-hospital-comprehensive-human-cancer-genome-data
Could migraine patients be doing more to get the most out of their medical visits? According to a new national survey released by the National Headache Foundation (NHF) and GlaxoSmithKline, the answer is yes. For the nearly 30 million migraine sufferers in the U.S., including six million treating with prescription medication, these survey results may have important implications.
The survey, conducted online in November 2010 by Harris Interactive, included 1,218 diagnosed migraine patients taking prescription medications for their migraine attacks as well as 533 physicians who treat between five and 10 migraine patients per week. The findings revealed disparities between what patients and physicians each reported typically discussing during office visits.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/glaxosmithkline/48596/
Designed to help developers obtain safety certifications, Texas Instruments Incorporated (TI) (NYSE: TXN) today announced its new Hercules safety microcontroller platform for medical, industrial and transportation applications. The platform consists of three ARM Cortex-based microcontroller families that deliver scalable performance, connectivity, memory and safety features for applications that require a high level of reliability. Unlike many microcontrollers that rely heavily on software for safety capabilities, Hercules microcontrollers implement safeguards in hardware to maximize performance and reduce software overhead. Coupled with robust tools, software and safety documentation, this functionality gives developers the headroom to differentiate their end products and speed time to market. For more information, visit www.ti.com/hercules-pr-lp.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/texasinstruments/39162/
OptiNose US Inc. today announced results of a study testing delivery of the migraine medicine sumatriptan with a novel device using OptiNose breath powered Bi-Directional™ nasal technology. In a direct comparison of drug absorption, the study found that OptiNose's sumatriptan product sent 62% more drug into the blood in the critical first 15 minutes than Imitrex® nasal spray (AUC 0-15 = 1.69 ng*hr/mL and 1.04 ng*hr/mL, respectively). The OptiNose technology achieved this improved effect despite delivering 20% less drug into the nose (16mg) than the Imitrex® liquid nasal spray (20mg).
To view Multimedia News Release, go to http://www.multivu.com/players/English/57713-optinose-innovative-breath-powered-nasal-delivery-technology-delivers-drugs-to-treat-variety-of-medical-conditions
Each year, 40 percent of all injury-related emergency room visits and 42 percent of all injury-related deaths happen between May and August.* Additionally, one in four children ages 14 and younger will sustain an injury that requires medical attention. The good news is that most of these injuries are preventable with education and simple precautions.
To view the Multimedia News Release, go to http://www.multivu.com/mnr/7141051-shriners-hospital-for-children-nascar-david-ragan-summer-safety
